Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

Samuel, Ryan M.; Majd, Homa; Richter, Mikayla N.; Ghazizadeh, Zaniar; Zekavat, Seyedeh Maryam; Navickas, Albertas; Ramirez, Jonathan T.; Asgharian, Hosseinali; Simoneau, Camille R.; Bonser, Luke R.; Koh, Kyung Duk; Garcia-Knight, Miguel; Tassetto, Michel; Sunshine, Sara; Farahvashi, Sina; Kalantari, Ali; Liu, Wei; Andino, Raul; Zhao, Hongyu; Natarajan, Pradeep; Erle, David J.; Ott, Melanie; Goodarzi, Hani; Fattahi, Faranak

SARS-CoV-2 infection has led to a global health crisis, and yet our understanding of the disease and potential treatment options remains limited. The infection occurs through binding of the virus with angiotensin converting enzyme 2 (ACE2) on the cell membrane. Here, we established a screening strategy to identify drugs that reduce ACE2 levels in human embryonic stem cell (hESC) derived cardiac cells and lung organoids. Target analysis of hit compounds revealed androgen signaling as a key modulator of ACE2 levels. Treatment with antiandrogenic drugs reduced ACE2 expression and protected hESC-derived lung organoids against SARS-CoV-2 infection. Finally, clinical data on COVID-19 patients demonstrated that prostate diseases, which are linked to elevated androgen, are significant risk factors and genetic variants that increase androgen levels are associated with higher disease severity. These findings offer insights on the mechanism of disproportionate disease susceptibility in men and identify antiandrogenic drugs as candidate therapeutics for COVID-19.